Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | EDNRB | P24530 | 2/20 | 0.47 |
| ▸ | EDNRA | P25101 | 2/20 | 0.47 |
| ▸ | PGR | P06401 | 3/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 3/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504570 | 0.91 | SCN9A (0.46) | EDNRBEDNRASCN5ASCN9AMEN1 | |
| SCHEMBL4501662 | 0.91 | PKM (0.48) | PKMEDNRBEDNRAPGRMEN1 | |
| SCHEMBL4504642 | 0.90 | PKM (0.50) | PKMEDNRBEDNRAPGRMEN1 | |
| SCHEMBL4500104 | 0.88 | HSD11B1 (0.50) | EDNRBEDNRASCN5ASCN9AMEN1 | |
| SCHEMBL4503018 | 0.87 | KDM1A (0.57) | PKMEDNRBEDNRAPGRL3MBTL1 | |
| SCHEMBL4488545 | 0.87 | MEN1 (0.49) | SCN5ASCN9AMEN1KMT2AHSD11B1 | |
| SCHEMBL4493747 | 0.86 | KMT2A (0.48) | MEN1KMT2AHSD11B1L3MBTL1 | |
| SCHEMBL4493785 | 0.85 | EDNRB (0.48) | PKMEDNRBEDNRAPGRL3MBTL1 | |
| SCHEMBL4507631 | 0.85 | AURKA (0.45) | PKMPGRSCN5ASCN9AHSD11B1 | |
| SCHEMBL4509330 | 0.85 | PGR (0.53) | PKMEDNRBEDNRAPGRHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211913-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-07-03 | — | — | US | claimed |
| US-20090149503-A1 | NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES | AMREIN KURT | 2009-06-11 | — | — | US | claimed |
| US-7528159-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | claimed |
| EP-1789041-B1 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | claimed |
| EP-1789041-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-05-30 | — | — | EP | claimed |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. | 2006-02-02 | — | — | US | claimed |
| WO-2006010546-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-02-02 | — | — | WO | claimed |
| US-8211913-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20090149503-A1 | NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES | AMREIN KURT | 2009-06-11 | — | — | US | disclosed |
| US-7528159-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1789041-B1 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| EP-1789041-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-05-30 | — | — | EP | disclosed |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. | 2006-02-02 | — | — | US | disclosed |
| WO-2006010546-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149503-A1 | NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES | GPR119, CYP4B1, SLC5A1 | PKM 1256/4885EDNRB 314/4885EDNRA 692/4885 |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | GPR119, CYP4B1, SLC5A1 | PKM 1256/4885EDNRB 314/4885EDNRA 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.